Local and systemic delivery of low molecular weight heparin following PTCA: Acute results and 6-month follow-up of the initial clinical experience with the porous balloon (Pilot-Study)

Catheterization and Cardiovascular Diagnosis

Volumn 44, Issue 3, 1998, Pages 267-274

  Oberhoff, Martin ^c   Baumbach, Andreas ^d   Hermann, Thomas ^d   Diehl, Claudia ^d   Maier, Rita ^d   Athanasiadis, Anastasios ^d   Herdeg, Christian ^d   Bonnet, Armin ^d   Haase, Karl K ^d   Voelker, Wolfram ^d   Baildon, Reinhard ^a   Veldhof, Susan ^b   Karsch, Karl R ^d  

^a Knoll AG   (Germany)

^b BOSTON SCIENTIFIC CORPORATION   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d NONE

Author keywords

Clinical study; Local drug delivery; PTCA; Restenosis

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DEVICE; DRUG DELIVERY SYSTEM; ELECTROCARDIOGRAM; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MALE; PATIENT SELECTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031832640     PISSN: 00986569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0304(199807)44:3<267::AID-CCD4>3.0.CO;2-3     Document Type: Article

References (35)

1. Popma JJ, Califf RM, Topol EJ: Clinical trials of restenosis after coronary angioplasty. Circulation 84:1427-1436, 1991.
2. Hanke H, Strohschneider T, Oberhoff M, Betz E, Karsch KR: Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res 67:651-659, 1990.
3. Liu MW, Roubin GS, King III SB: Restenosis after coronary angioplasty: Potential biological determinants and role of intimal hyperplasia. Circulation 79:1374-1387, 1989.
4. Herrmann JPR, Hermans WRM, Vos J, Serruys PW: Pharmacological approaches to the prevention of restenosis following angioplasty: The search for the Holy Grail? (part I). Drugs 46:18-52, 1993.
5. Herrmann JPR, Hermans WRM, Vos J, Serruys PW: Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail? (part II). Drugs 46:249-262, 1993.
6. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamenz J, Schmid KM, Betz E, Karsch KR: Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circulation 85:1548-1556, 1992.
7. Herbert JM, Maffrand JP: Heparin interactions with cultured human vascular endothelial and smooth muscle cells: Incidence on vascular smooth muscle cell proliferation. J Cell Physiol 138:424-432, 1989.
8. Gimple LW, Gertz SD, Haber HL, Ragosta M, Powers ER, Roberts WC, Sarembock IJ: Effect of chronic subcutaneous or intramural administration of heparin on femoral artery restenosis after balloon angioplasty in hypercholesterolemic rabbits. Circulation 86:1536-1546, 1992.
9. Berk BC, Gordon JB, Alexander RW: Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 17:111B-117B, 1991.
10. Grassman ED, Leya FS, Lewis BE, Johnson SA, Moran JF, Fareed J, Wolf H: The low molecular weight heparin certoparin may significantly prevent restenosis following balloon coronary angioplasty. Circulation 96:I-323, 1997.
11. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, Ohmen M, ERA Investigators: Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation 90:908-914, 1994.
12. Karsch KR, Preisack MB, Bonan R, on behalf of the REDUCE Study Group: Low molecular weight heparin, reviparin, in prevention of restenosis after PTCA: Results of the REDUCE trial. J Am Coll Cardiol 27:113A (abstract), 1996.
13. Wolinsky H, Thung SN: Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 15:475-481, 1990.
14. Wilensky RL, March KL, Hathaway DR: Direct intraarterial wall injection of microparticles via a catheter. A potential drug delivery strategy following angioplasty. Am Heart J 122:1136-1140, 1991.
15. Baumbach A, Oberhoff M, Rübsamen K, Jochims K, Herdeg C, Kranzhöfer A, Safer A, Karsch KR: Porous balloon delivery of low molecular weight heparin in the dog coronary artery.A safety study. Eur Heart J 17:1538-1545, 1996.
16. Oberhoff M, Herdeg C, Baumbach A, Shamet K, Kranzhöfer A, Weingärtner O, Rübsamen K, Kluge M, Karsch KR: Time course of smooth muscle cell proliferation after local drug delivery of low molecular weight heparin using a porous balloon catheter. Cath Cardiovasc Diag 41:268-274, 1997.
17. Okin PM, Kligfield P: Effect of exercise protocol and lead selection on the accuracy of heart rate-adjusted indices of ST-segment depression for detection of three-vessel coronary artery disease. J Electrocardiol 22:187, 1989.
18. Hermans WR, Rensing PJ, Foley DP, de Feyter PJ, Serruys PW: Therapeutic dissections after successful coronary balloon angioplasty: No influence on restenosis or on clinical outcome in 693 patients. The MERCATOR study group. J Am Coll Cardiol 20(4):767-780, 1992.
19. Baumbach A, Haase KK, Voelker W, Mauser M, Karsch KR: Effects of intracoronary nitroglycerin on lumen diameter during early follow-up angiography after coronary excimer laser atherectomy. Eur Heart J 12:726-731, 1991.
20. Fleck E, Maier-Rudolf W, Oswald H: Coronary angiography and interventional cardiology. Curr Opin Radiol 3(4):550-560, 1991.
21. Light TJ Jr., Bellan JA, Roberts MP, Force SD, Chen IL, Kerstein MD, Kadowitz PJ, McNamara DB: Heparin treatment enhances the recovery of neoendothelial acetylcholin-induced vascular relaxation after balloon catheter injury in the rabbit aorta. Circulation 88:413-419, 1993.
22. Clowes AW, Clowes MM: Kinetics of cellular proliferation after arterial injury: II. Inhibition of smooth muscle growth by heparin. Lab Invest 52:611-616, 1985.
23. Castellot JJ Jr, Cochran D, Karnovsky M: Effect of heparin on vascular smooth muscle cells. J Cell Physiol 124:21-28, 1985a.
24. Au YPT, Kenagy RD, Clowes MM, Clowes AW: Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis 23 (suppl. 1):177-182, 1993.
25. Castellot JJ Jr, Wong K, Herman B Hoover ,RL, Albertini DF, Wright TC, Caleb BL, Karnovsky MJ: Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 124:13-20, 1985b.
26. Pukac LA, Castellot JJ Jr, Wright TC Jr, Caleb BL, Karnovsky MJ: Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul 1:435-443, 1990.
27. Geary RL, Koyama N, Wang TW, Vergel S, Clowes AW: Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries. The role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation. Circulation 91:2972-2981, 1995.
28. Wilcox JN, Harker LA, Kelly AB, Lumsden AB, Carey KD, Ollerenshaw J, Willis AL, Hanson SR: Inhibition of vascular lesion formation in the non-human primate using a chemically modified heparin derivate, astenose. Circulation 90:Suppl I-296 (abstract), 1994.
29. Wilensky RL, March KL, Gradus-Pizlo I, Schauwecker D, Michaels M, Robinson J, Carlson K, Hathaway DR: Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am Heart J 129:852-859, 1995.
30. Lovich A, Edelman ER: Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Circ Res 77:1143-1150, 1995.
31. Hämmerte H, Betz E, Herr D: Human endothelial cells are stimulated and vascular smooth muscle cells are inhibited in their proliferation and migration by heparins. VASA 20:207-215, 1991.
32. Herdeg C, Oberhoff M, Baumbach A, Haase KK, Horch B, Kranzhoefer A, Karsch KR: Local drug delivery with porous balloons in the rabbit: Assessment of vascular injury for an improvement of application parameters. Cathet Cardiovasc Diag 41:308-314, 1997.
33. Foley DP, Melkert R, Serruys PW on behalf of the CARPORT, MERCATOR, MARCATOR, and PARK Investigators: Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation 90:1239-1251, 1994.
34. Hermans WRM, Rensing BJ, Kelder JC, de Feyter PJ, Serruys PW: Postangioplasty restenosis rate between segments of the major coronary arteries. Am J Cardiol 69:94-200, 1992.
35. Hirshfeld JW, Schwartz S, Jugo R, and the M-HEART investigators: Restenosis after coronary angioplasty: A multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 18:647-656, 1991.